Clene (CLNN) director linked LLC buys stock and new warrant units
Rhea-AI Filing Summary
Clene Inc. director Alison Mosca reported indirect ownership changes tied to entities she is associated with, mainly Kensington Clene 2021, LLC. On January 9, 2026, Kensington Clene 2021, LLC made an in-kind distribution of 57,219 shares of common stock and matching Tranche A and Tranche B warrants for no consideration, leaving it with 263,833 common shares and 62,500 Tranche A and 62,500 Tranche B warrants held indirectly. On January 13, 2026, under a Securities Purchase Agreement effective that day, Kensington Clene 2021, LLC acquired 16,667 common shares at $6.00 per share plus 20,000 Series A warrants and 46,667 Series B warrants, all held indirectly. Additional common shares are reported as indirectly held through Kensington Investments, L.P. and the Robert C. Gay 1998 Family Trust, with Ms. Mosca disclaiming beneficial ownership where she has no pecuniary or profits interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Series A Warrants (Right to buy) | 20,000 | $0.00 | -- |
| Grant/Award | Series B Warrants (Right to buy) | 46,667 | $0.00 | -- |
| Grant/Award | Common Stock | 16,667 | $6.00 | $100K |
| Other | Tranche B Warrants (Right to buy) | 57,219 | $0.00 | -- |
| Other | Tranche A Warrants (Right to buy) | 57,219 | $0.00 | -- |
| Other | Common Stock | 57,219 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The transaction reported on this line represents a distribution in kind by the limited liability company to a limited partner for no consideration. The securities are owned by Kensington Clene 2021, LLC. Ms. Mosca is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest. Kensington Clene 2021, LLC entered into a Securities Purchase Agreement with Clene Inc. and the other parties thereto, dated January 8, 2026, for the purchase of 16,667 shares of the Company's common stock, Series A Warrants to purchase 20,000 shares of the Company's common Stock and Series B Warrants to purchase 46,667 shares of the Company's common stock, closing effective January 13, 2026. The price of each Unit is $6.50; one Unit consists of one share of Common Stock of Clene Inc., one Series A Warrant and one Series B Warrant. The securities are owned by the Kensington Investments, L.P. Ms. Mosca is the chief executive officer of Kensington Investments, L.P. The shares owned by the Kensington Investments, L.P. may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Investments, L.P., for which she does not have a pecuniary or profits interest. The securities are owned by the Robert C. Gay 1998 Family Trust. Ms. Mosca is the trustee of the Robert C. Gay 1998 Family Trust. The shares owned by the Robert C. Gay 1998 Family Trust may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca has no pecuniary or profits interest in the shares held by the Robert C. Gay 1998 Family Trust. The Tranche B Warrants will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the FDA approval of a New Drug Application from the Company. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest. The Tranche A Warrants will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the FDA accepts a New Drug Application from the Company. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest. The exercise price for each Series A Warrant will increase from $6.00 to $7.00 per share if either: (a) the warrant is exercised prior to the Company's public announcement of the U.S. Food and Drug Administration's (the "FDA") posted action date under the Prescription Drugs User Fee Act for the Company's new drug application ("NDA") for CNM-Au8 (the "Series A Trigger Announcement") or (b) the volume-weighted average price (the "VWAP") of the Company's common stock equals or exceeds $10.00 on the measurement date associated with the Series A Trigger Announcement. The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price. The exercise price for each Series B Warrant will increase from $6.00 to $12.50 per share if: (i) the Series B Warrant is exercised prior to the Company's public announcement of its receipt of written approval from the FDA of its NDA for CNM-Au8 in ALS or (ii) the VWAP of the Company's common stock is equal to or greater than $25.00 on the associated measurement date. The exercise price of the Series B Warrant will increase to $10.00 per share if the VWAP of the Company's common stock is equal to or greater than $20.00 on the associated measurement date. The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price.
FAQ
What insider transactions did Clene (CLNN) disclose for Alison Mosca?
The filing shows indirect transactions by entities associated with director Alison Mosca, including an in-kind distribution and new purchases of common stock and warrants through Kensington Clene 2021, LLC.
What new securities tied to Clene did Kensington Clene 2021, LLC acquire on January 13, 2026?
On January 13, 2026, Kensington Clene 2021, LLC acquired 16,667 common shares at $6.00 per share, plus 20,000 Series A warrants and 46,667 Series B warrants to purchase Clene common stock.
What was the structure and price of the Clene units purchased by Kensington Clene 2021, LLC?
Each unit was priced at $6.50 and consisted of one Clene common share, one Series A warrant, and one Series B warrant.
How are the Tranche A and Tranche B warrants on Clene stock structured for expiration?
The Tranche A warrants expire on the earlier of June 16, 2026 or 60 days after FDA acceptance of a New Drug Application, while the Tranche B warrants expire on the earlier of June 16, 2030 or 60 days after FDA approval of a New Drug Application.